Founded in 2015, AssayQuant Technologies develops real-time biochemical assay platforms for measuring kinase and phosphatase activity. The company specialises in enzyme activity analysis for drug discovery and cell signalling research. Its proprietary PhosphoSens® technology uses fluorescent sensor peptide substrates to directly monitor catalytic activity and generate continuous kinetic data. This approach enables researchers to study enzyme regulation, quantify inhibitor potency, investigate selectivity, and characterise mechanisms of action. AssayQuant Technologies supports applications across oncology, inflammation, metabolic disease, signal transduction, and broader therapeutic target discovery programmes.
The company’s portfolio includes kinase activity assays, phosphatase activity assays, active recombinant enzymes, peptide substrates, and cell lysate assay systems. Assays are available for hundreds of kinase and phosphatase targets and are designed for biochemical screening, compound profiling, and preclinical research workflows. AssayQuant Technologies also provides KinSight profiling services and custom substrate development for novel targets. The PhosphoSens® platform supports kinetic measurements, time-resolved fluorescence formats, and activity analysis in endogenous cell and tissue lysates. These tools support generation of quantitative functional data for target validation, lead optimisation, and inhibitor characterisation.
Europa Biosite distributes for AssayQuant Technologies in Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Norway, Sweden, Switzerland and the United Kingdom.
